期刊名称：AAPS PHARMSCITECH
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.
AAPS PharmSciTech publishes six issues a year.
Related subjects » Biochemistry & Biophysics - Biotechnology - Pharmacology & Toxicology
Abstracted/Indexed in
Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, PubMedCentral, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, CSA, Academic OneFile, Expanded Academic, International Pharmaceutical Abstracts, OCLC, SCImago, Summon by ProQuest
Instructions to Authors
Instructions for Authors
AAPS PharmSciTech
The following instructions pertain to submissions to the American Association of Pharmaceutical Scientists’ electronic journals: The AAPS Journal and AAPS PharmSciTech.
INTRODUCTION
AAPS PharmSciTech (ISSN 1530-9932) is a peer-reviewed online-only journal owned by the American Association of Pharmaceutical Scientists. The journal's mission is to disseminate scientific and technical information on drug product design, development, evaluation and processing to the global pharmaceutical research community. The Journal is indexed by PubMed/Medline, Index Medicus, Institute of Scientific Information's Science Citation Index Expanded® and Chem Abstracts.
Editor-in-Chief, Lee E. Kirsch, Ph.D., oversees an international editorial board of leading researchers in the pharmaceutical sciences. Dr. Kirsch is professor of pharmacy at the University of Iowa, College of Pharmacy.
TYPE OF MANUSCRIPTS
AAPS PharmSciTech publishes the following article types. For examples of published articles, please visit www.Pharmagateway.net.
Reviews, usually by invitation and organized into themed issues, report on recent advances in pharmaceutical research.
Mini-Reviews discuss a more narrowly focused topic of recent research. Unsolicited reviews are considered only if they are authored by investigators who have demonstrated expertise in the relevant areas.
Original Research Papers contain innovative, hypothesis-driven research that is supported by sound experimental design, methodology, and data interpretation.
Brief Technical Notes, normally more limited in scope than Original Research Papers, must be of high quality, general interest, and sufficient importance to warrant publication.
Rapid Communications provide a venue for fast-breaking research updates or other news items. The justification for rapid communication should be stated in the cover letter during submission.
Regulatory Notes provide a summary of regulatory decisions made and rationale for the regulatory decision made on a product. These notes are typically submitted by invitation only, but Authors may propose notes to the Editors.
Editorials, Commentaries or Summaries are usually published by invitation only. These articles contain topical issues of public and scientific interest.
Meeting Reports on AAPS or AAPS-affiliated meetings provide readers with summaries of such meetings, including consensus views. When a meeting report purports to be a Consensus Report, authors should review and adhere to the Consensus Report Review and Publishing Guidelines available at http://www.aapspharmaceutica.com/inside/refguide/ConsensusReport-2007.pdf. The corresponding author must complete and submit the Corresponding Author’s Consent to Publish Consensus Report (http://www.aapspharmaceutica.com/inside/refguide/Consensus_Rpt_-_Corresponding_Author_Consent_Form.pdf) and all contributing authors must complete and submit the Contributing Author’s Consent to Publish Consensus Report , available at http://www.aapspharmaceutica.com/inside/refguide/Consensus_Rpt_-_Contributing_Author_Consent_Form.pdf.
Meeting Notices
A Meeting Notice provides readers with information on an upcoming AAPS or AAPS-affiliated meeting, including title of the meeting, date, time, location, an outline and description of meeting topics, and a list of invited speakers. If possible, Meeting Notices should include contact information for the organizers and a URL to the meeting’s webpage. Meeting Notices should be submitted to the AAPS Editorial Office two to three months prior to the meeting.
Letters to the Editor: May be submitted by readers commenting on articles already published by the Journal.
All articles published in the journal will follow the Springer Online First production workflow, enabling publication on the SpringerLink website after receipt of author corrections to page proofs.
MANUSCRIPT SUBMISSION
AAPS uses Editorial Manager™ as its peer review tracking system. Manuscripts must be submitted online by the Corresponding Author at www.editorialmanager.com/aapspt/. You may be required to register as a new user with Editorial Manager upon your first visit. Straightforward login and registration procedures can be found on the website. Editorial Manager allows authors to track the progress of manuscript review in real time. Detailed, step-by-step instructions for submitting manuscripts can be found on the website. Manuscripts must be created and saved in Microsoft® Office Word for Windows (Editorial Manager and AAPS cannot accommodate files created in the new Microsoft Office Word .docx file format at this time). All correspondence regarding your manuscript must go through Editorial Manager.
Special Features, Appendices and Supplementary Material
Can be accommodated and may contain highly interactive features or large databases. All authors are encouraged to take full advantage of the Web-only capabilities of online publishing, including 3-D, video, and interactive graphics. If a desired technical feature is not covered in the Author's Instructions, please contact the AAPS Editorial Office (AAPSPTsubmit@aaps.org) for assistance. All special features must be created by the Author.
Authors who wish to publish electronic supplementary material to their article (Excel files, images, audio/video files) must submit the supplementary files/materials with their manuscript submission via our online peer review tracking system, Editorial Manager. These files may be submitted as one file or multiple files as desired by the authors. Accepted formats for these files include .doc, .docx, .xls, .xlsx, .jpeg, .pdf, and for videos, mpeg-3 format. Note that supplementary files are not automatically included in the reviewer PDF. Please therefore note in a cover letter if these materials should be evaluated by reviewers only, or if the supplemental files should be included for review and be published with the article should the manuscript be accepted for publication. If the supplemental files are intended for publication, callouts using supplemental1, supplemental 2, etc. should be placed in the appropriate location within the text of the manuscript body.
Hypertext Links
Authors may identify uniform resource locators (URLs) for websites that provide the reader with additional information on the topic addressed in the manuscript. Although URLs are an important feature of electronic publishing, authors are encouraged to be selective in their choice of sites to include. Do not include URLs for web pages with newspaper or journal articles that will be removed or archived to another web page. Links to pharmaceutical manufacturers or other sources of product information are acceptable; however, providing a URL to the reader should not be substituted for adequate discussion within the manuscript itself. Do not include links to sites that are not accessible without a password.
TERMS OF MANUSCRIPT CONSIDERATION
AAPS Journals Ethics Policy
The Editors-in-Chief of the three Journals of AAPS: Pharmaceutical Research, The AAPS Journal, and AAPS PharmSciTech, along with the AAPS Publications Committee developed an integrated ethics policy to guide decision-making across the three Journals. The document is based on the recommendations on publication ethics policies for medical journals published by the World Association of Medical Editors (WAME), posted at http://wame.org/resources/ethics-resources, and subscribed to by almost 1,000 journals.
Authors are required to review and adhere to the AAPS Journals Ethics Policy (http://www.aaps.org/JournalsEthics) in full prior to submitting manuscripts to AAPS PharmSciTech. Excerpts from the Policy are outlined below.
Full Disclosure
During the manuscript submission process, all authors will be required to confirm that the manuscript has not been previously published in any language anywhere and that it is not under simultaneous consideration by another journal. The Journal policy regarding compound disclosure centers on the data presented. If specific data relating to the study compound are reported then the Journal requires identification so that reviewers and readers can judge, based on general principles, whether the data are plausible and internally consistent, and to potentially allow future examination and/or validation of the results and conclusions reported. If however a library of compounds is used to generate correlations, such as in QSAR when the scope and diversity of the compounds are described, then it is possible that the specific chemical compositions of the compounds need not be identified, subject to the discretion of the reviewers and the Editor.
Conflicts of Interest
Authors will be required to declare all conflicts of interest (or their absence) during the submission of a manuscript. This conflict declaration includes conflicts or potential conflicts of all listed authors. If any conflicts are declared, AAPS will publish them with the paper. In cases of doubt, the circumstance should be disclosed so that the editors may assess its significance.
Conflicts may be financial, academic, commercial, political or personal. Financial interests may include employment, research funding (received or pending), stock or share ownership, patents, payment for lectures or travel, consultancies, nonfinancial support, or any fiduciary interest in a company.
Copyright Transfer
The Copyright Revision Act of 1976 (Public Law 94-533) requires that Authors transfer their copyrights to the Publisher, American Association of Pharmaceutical Scientists, in order to provide for the widest possible dissemination of professional and scientific literature. A signed Transfer of Copyright form must be submitted online with the manuscript. The Transfer of Copyright form for an accepted manuscript must be on file with the AAPS Editorial Office prior to production for publication. Corresponding Authors may print and sign the form on behalf of all authors The Transfer of Copyright form can be found at http://www.aapsj.org/copyright/copyright.
Ethics in Animal and Clinical Investigations
Human Subjects and Clinical Trials
AAPS Journals require author(s) at the time of manuscript submission to make a statement in the cover letter, indicating documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) for all studies involving people, medical records, and human tissues, per the uniform guidelines from the World Medical Association (http://www.wma.net/en/30publications/10policies/index.html).
Studies and research using human subjects, medical records, and human tissues (including educational research) must also state this compliance within the Methods Section.
The AAPS Journals also require that controlled clinical trials must be registered in a publicly available database or the Journals will not publish the results of these trials. Manuscripts submitted to the Journals must include trial registration information in the cover letter. To register a clinical trial, authors should go to the NIH registry (www.clinicaltrials.gov) or the International Standard Randomized Controlled Trials database (http://isrctn.org). Further information can be obtained from the International Committee of Medical Journal Editors (ICMJE) at
http://www.icmje.org/publishing_10register.html.
Animal Use and Assurances
AAPS Journals require author(s) at the time of manuscript submission to make a statement in the cover letter, indicating that animal experiments are conducted in full compliance with local, national, ethical, and regulatory principles and local licensing regulations, per the spirit of Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International’s expectations for animal care and use/ethics committees (http://www.aaalac.org/education/module_1.cfm). Investigations using experimental animals (including educational research) must also state this compliance within the Methods Section.
Originality of Manuscripts
Authors of manuscripts submitted to the American Association of Pharmaceutical Scientists are obliged to present accurate representation of the research performed along with an objective discussion of the significance of their findings. The author’s submission should be original work that reflects research undertaken with integrity and honesty, and that conforms to ethical practices outlined in the AAPS Journals Ethics Policy. Authors should be willing to reply to any reasonable request from editors, referees, and scientist for materials, methods, or data necessary for verification of the conclusions reported in the paper.
Use of Copyrighted Tables and Figures
A copy of the granted permission to use copyrighted figures and tables must be included with the submitted manuscript.
Peer Review
All submissions will be reviewed anonymously by at least two independent Reviewers. Authors are encouraged to submit names and email addresses of expert reviewers, but selection remains a prerogative of the Editors. Authors may include supplementary notes to facilitate the review process. If an accepted paper is cited that has not yet appeared in print and is required for evaluation of the submitted manuscript, authors should provide an electronic version for use by the Reviewers. Authors are responsible for all statements in their work, including changes made by the copyeditor after a manuscript is accepted.
MANUSCRIPT ORGANIZATION
Several components of the manuscript must be submitted as individual files within Editorial Manager: cover letter, title page, manuscript body (including references list), individual figure files, and the Transfer of Copyright.
(* indicates item is required for all manuscript types, unless otherwise specified)
Cover Letter
A Cover Letter is recommended, but not required. Please note, a cover letter is required for a Rapid Communication.
Authors who wish to submit names and email addresses of recommended reviewers for the peer review process may also indicate those in the Cover Letter.
*Title Page
The title page must be submitted as a separate file, and should include the title of the article, author names with full first name (no degrees), each author’s affiliation, and a suggested running head (of less than 50 characters, including spaces). The affiliation should comprise the department, institution (usually university or company), city, and state (or nation) and should be typed as a footnote to the author’s name. For the corresponding author designated to correspond with the Editorial Office and review proofs, indicate his/her complete mailing address, office/cellular telephone number, fax number, and e-mail address.
*Transfer of Copyright Form:
A signed copy of the Transfer of Copyright must be submitted online as part of the manuscript submission process. The Transfer of Copyright is available at
http://www.aaps.org/uploadedFiles/Content/Publications/Journals/Transfer of Copyright 2011.pdf
Abstract
Only Reviews, Mini Reviews, Original Research Articles, Rapid Communications and Meeting Reports require an abstract. The abstract is limited to 250 words or less. For Research Articles, the abstract should include a brief (2 to 3 sentences) statement for each of the following sections: Introduction, Methods and Materials, Results and Discussion, and Conclusion written in paragraph form. All abstracts must be written in one paragraph, with no subheadings, equations, tables, reference citations or graphics.
*Keywords
Provide a list of no more than 5 key words.
Introduction
Required for Reviews, Mini Reviews, Original Research Articles, and Meeting Reports only.
*Main Text Body
Please include continuous line numbers in the manuscript body file.
For Original Research Articles, Brief Technical Notes, Rapid Communications, organize the main text as follows: Introduction, Materials and Methods, Results, Discussion, and Conclusion. Combining Results and Discussion is discouraged. The use of subheadings to divide the text is encouraged. Primary, Secondary, and Third level headings should be clearly defined, but do not use numbers or letters.
Recommended word counts are as follows: Reviews, Original Research Articles and Meeting Reports: 5000; Mini Reviews: 2500; Brief Technical Reports/Note, and Rapid Communications: 1200.
Use abbreviations sparingly, and define them at the first insertion in the text. Define all abbreviations used in tables within the table footnotes Use the metric system for all measurements. Express metric abbreviations in lowercase letters without periods (cm, mL, sec). Define all symbols used in equations and formulas. When symbols are used extensively, the authors may include a list of all symbols in a table.
Numbers should be reported to reflect the precision of the instrumentation utilized. Calculated numbers, such as means and standard deviations, should be expressed to no more than one significant digit beyond the precision of the instrument. Normally, data reported to more than 3 significant figures should be justified. The precision of the variability (e.g., standard deviation) should not exceed that of the reported mean value.
Conclusion
The conclusion should be a brief paragraph, containing 3 to 4 sentences, that summarizes the findings presented
Acknowledgments
Include funding source(s) and other contributions. If the work has been funded by NIH, please provide name(s) of funding institute(s) and grant number(s). This information is required for automatic deposit into PUBMED Central by the Publisher.
References
References should conform to Vancouver style and be numbered consecutively in the order in which they are cited in the text. Cite in the text by the appropriate Arabic numeral enclosed in parentheses, e.g., (1), (2-5), etc.
Maximum reference limits are as follows: Reviews, Original Research Articles and Meeting Reports: 100; Mini Reviews: 40; Brief Technical Notes and Rapid Communications: 20.
References to unpublished peer-reviewed, personal communications, including conference abstracts, and papers in preparation or in review, cannot be listed, but can be notated parenthetically in the text.
Abbreviations for journal names should conform to those of Vancouver style. The style and punctuation of the references should conform to the following examples:
Type Example
1. Journal article Smith JJ. The world of science. Am J Sci. 1999;36:234–5.
2. Journal article with DOI (and with page numbers) O'Mahony S, Rose SL, Chilvers AJ, Ballinger JR, Solanki CK, Barber RW, et al. Finding an optimal method for imaging lymphatic vessels of the upper limb. Eur J Nucl Med Mol Imaging. 2004;31:555–63. doi:10.1007/s00259-003-1399-3.
3. Journal article by DOI (before issue publication with page numbers) O'Mahony S, Rose SL, Chilvers AJ, Ballinger JR, Solanki CK, Barber RW, et al. Finding an optimal method for imaging lymphatic vessels of the upper limb. Eur J Nucl Med Mol Imaging. 2004. doi:10.1007/s00259-003-1399-3.
4. Article in electronic journal by DOI (no paginated version) Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 2000. doi:10.1007/s801090000086.
5. Journal article in a supplement Frumin AM, Nussbaum J. Esposito M. Functional asplenia: demonstration of splenic activity by bone marrow scan. Blood 1979; 59 Supple 1:26-32.
6. Book chapter Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251–306.
7. OnlineFirst chapter in a series (without a volume designation but with a DOI) Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108.
8. Book, authored Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.
9. Online document Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.
10. Online database Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. Accessed 21 Sept 1998.
11. Supplementary material/private homepage Doe J. Title of supplementary material. 2000.
http://www.privatehomepage.com. Accessed 22 Feb 2000.
12. University site Doe, J.: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999).
13. FTP site Doe, J.: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 Nov 1999. Accessed 25 Dec 1999.
14. Organization site ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007.
For a full description of the Vancouver reference style, including numerous examples, please access
http://www.nlm.nih.gov/bsd/uniform_requirements.html
Tables
Tables must be created in Microsoft Word table format. Tables should be numbered (with Roman numerals) and referred to by number in the text. Center the title above the table, and type explanatory footnotes (indicated by superscript lowercase letters) below the table. Data must be placed in separate cells of the table to prevent text and numbers from shifting when the table is converted for publication on the Internet. Empty cells may be inserted to create spacing. Tables should not duplicate information provided in the text. Instead, tables should be used to provide additional information that illustrates or expands on a specific point the author wishes to make. Each table should be self-explanatory.
Figures
AAPS PharmSciTech offers authors the use of color figures in online published manuscripts, free of charge. Figures (as well as photographs, drawings, diagrams, and charts) are to be numbered in one consecutive figures should be separated from the text, and collated in a separate section called ’’Legend to Figures. All Electronic artwork must be submitted online via our online peer review tracking system, Editorial Manager. Figure files should be submitted in TIFF or EPS format (1200 dpi for line and 300 dpi for half-tones and gray-scale art); however, .jpeg, .gif, and .bmp files may also be submitted as long as the dpi specifications above are met. Use of a professional graphics program such as Adobe® Photoshop to edit and/or save photographs and graphics is highly recommended. Because of difficulties with exporting graphics from Microsoft PowerPoint, original graphics (those imported into PowerPoint) must be saved in an acceptable file format (above). Microsoft PowerPoint and Microsoft Word figure files will not be accepted.
The maximum combined count for tables and figures are as follows: Reviews, Original Research Articles and Meeting Reports: 10 (suggested); Mini Reviews: 6, Brief Technical Notes, and Rapid Communications: 6.
DOES SPRINGER PROVIDE ENGLISH LANGUAGE SUPPORT?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in all areas Springer publishes in.
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
Footnotes
Footnotes should be avoided. When their use is absolutely necessary, footnotes should be numbered consecutively using Arabic numerals and should be typed at the bottom of the page to which they refer. Place a line above the footnote, so that it is set off from the text. Use the appropriate superscript numeral for citation in the text.
Editorial Board
Editor-in-Chief:
Lee Kirsch, University of Iowa, Iowa City, Iowa USA
Associate Editors:
Melgardt M. De Villiers, University of Wisconsin, Madison, Wisconsin, USA;
Hong-Shian Huang, University of Iowa, Iowa City, Iowa, USA;
Paul Myrdal, University of Arizona, College of Pharmacy, Tucson, Arizona, USA;
Michael Repka, University of Mississippi, School of Pharmacy, Oxford, Mississippi USA;
Editorial Advisory Board:
Fernando Alvarez-Núñez, Small Molecule Pharmaceutical Research and Development, Amgen, Los Angeles, California, USA;
Larry Augsburger, University of Maryland, College Park, Maryland USA;
Sunil Battu, Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA;
Gayle Brazeau, University at Buffalo, SUNY, Buffalo, New York USA;
Harry Brittain, Center for Pharmaceutical Physics, Milford, New Jersey USA;
Robin Bogner, Department of Pharmaceutical Science, University of Connecticut, Storrs, Connecticut, USA;
Stephen R. Byrn, Purdue University, West Lafayette, Indiana, USA;
Carla Caramella, University of Pavia, Pavia, Italy;
Chiao-Hsi Chiang, School of Pharmacy, National Defense Medical Center, Taiwan;
Mahavir B. Chougule, College of Pharmacy, University of Hawaii at Hilo, Hawaii, USA;
Paolo Colombo, University of Parma, Parma, Italy;
Damrongsak Faroongsarng, Department of Pharmaceutical Technology, Prince of Songkla University, Hat Yai, Thailand;
Andrea Gazzaniga, University of Milan, Milan, Italy;
Anthony J. Hickey, University of North Carolina, Chapel Hill, North Carolina USA;
Munir A. Hussain, Bristol-Myers Squibb, New Brunswick, New Jersey, USA;
Mansoor Khan, Food and Drug Administration, Silver Spring, Maryland, USA;
Peter Kleinebudde, Heinrich Heine University, Düsseldorf, Germany;
Gregory Knipp, Purdue University, West Lafayette, Indiana, USA;
Kang C. Lee, Sung Kyun Kwan University, Seoul, South Korea;
Ping I. Lee, University of Toronto, Toronto, Canada;
Wilna Liebenberg, North-West University in Potchefstroom, South Africa;
Jim Litster, Purdue University, West Lafayette, Indiana, USA;
Soumyajit (Jit) Majumdar, Research Institute of Pharmaceutical Sciences, The University of Mississippi, Oxford, Mississippi, USA;
Walaisiri Muangsiri, Academic Affairs at Faculty of Pharmaceutical Sciences; Chulalongkorn University, Thailand;
Praneet Opanasopit, Green Innovations Group, Silpakorn University, Bangkok, Thailand;
Kamla Pathak, Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, India;
Viness Pillay, Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg, South Africa;
Feng Qian, Department of Pharmacology and Pharmaceutical Sciences, Tsinghua University, Beijing, China;
Jay Babu Ramapuram, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA;
Jean Paul Remon, Ghent University, Ghent, Belgium;
Claudio Salomon, Faculty of Biochemical and Pharmaceutical Sciences, University of Rosario, Santa Fe, Argentina;
Ramesh Srirangam, Abon Pharmaceuticals, Northvale, New Jersey, USA;
Socrates Tabosa do Egito, Departamento de Farmacia, Universidade Federal do Rio Grande do Norte, Brazil;
Peter L. D. Wildfong, Duquesne University, Pittsburgh, Pennsylvania, USA;
Dale E. Wurster, University of Iowa School of Pharmacy, Iowa City, Iowa, USA;
Peter York, University of Bradford, West Yorkshire, United Kingdom
Meet the Editor-in-Chief and Associate Editors
Meet the Editor-in-Chief and Associate Editors
Lee E. Kirsch, Ph.D. - EDITOR-IN-CHIEF
Lee E. Kirsch, Professor of Pharmaceutics and Biochemical and Chemical Engineering at the University of Iowa, received his B.S. (1975) from Purdue University and his Ph.D. (1982) from The Ohio State University in pharmaceutical chemistry. He was an industrial scientist and group leader for 12 years at Lilly Research Laboratories before joining the faculty at Iowa in 1995. He is the Chair-Elect of the faculty committee for the National Institute of Pharmaceutical Technology and Education (NIPTE).
He is an active member of the American Association of Pharmaceutical Scientists and the Parenteral Drug Association. He was the editor of the PDA Journal of Pharmaceutical Science and Technology from 2000 to 2008 and is currently the editor-in-chief of the AAPS PharmSciTech.
Melgardt M. De Villiers, Ph.D. - ASSOCIATE EDITOR
Melgardt M. De Villiers, Ph.D. is currently an Associate Professor at the University of Wisconsin School of Pharmacy. He earned a B. Pharm in Pharmacy, M.Sc., and Ph.D., in Pharmaceutics also a D.T.E. degree in Higher Education all from North-West University, South Africa and his Post-doc in Pharmaceutics from the University of Iowa, College of Pharmacy working with Prof. Dale Eric Wurster.
His past professional experience includes Adjunct Professor at the School of Pharmacy, North-West University, South Africa, Associate Professor in the Division of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, USA and the Department of Pharmaceutics, North-West South Africa.
His current research is focused on determining the Pharmaceutical science involved in developing an understanding of the pharmaceutics, engineering, and materials sciences principles underlying enhanced drug delivery technologies. Several of his publications have been related to layer-by-layer nanocoating and to solid-state properties of drugs and excipients.
Dr. De Villiers is a recipient of the Outstanding Professor in the College of Health Sciences at the University of Louisiana at Monroe.
Hong-Shian Huang, Ph.D. - ASSOCIATE EDITOR
Dr. Hong-Shian (Greg) Huang received his bachelor’s degree in pharmacy from National Defense Medical Center (NDMC), Taipei, Taiwan and his PhD in pharmaceutics from the University of Iowa in 1982.
Upon completion of his graduate study, he served as a research scientist and associate professor at NDMC. He taught pharmaceutics courses and conducted research on purification of antibiotics from fermentation broth, drug absorption through GI tract, and artificial skin and burn dressing development.
In 1990, Dr. Huang returned to the University of Iowa as a visiting professor. Later he was appointed research scientist and then quality control manager for Pharmaceutical Services. During the 13 years at Iowa, his responsibilities included dosage form development, analytical method development and validation, preformulation, chemical stability study and quality control.
In 2003, he joined Ivax Research Inc., Miami, as director of analytical R & D. At Ivax he was in charge of analytical method development and validation in support of the generic drug development. In addition he managed analytical support for veterinary drugs as well as quality control and stability study of marketed paclitaxel injections.
Dr. Huang currently serves as a research scientist for the department of pharmaceutics, the University of Iowa.
Paul Myrdal, Ph.D. - ASSOCIATE EDITOR
Dr. Myrdal is an Associate Professor of Pharmaceutics at the University of Arizona. He received his B.S. in Molecular and Cellular Biology (1989) and his Ph.D. in Physical Pharmaceutical Chemistry from the University of Arizona (1994). Dr. Myrdal joined the University of Arizona, College of Pharmacy during the fall of 2000. Prior to his faculty appointment, Dr. Myrdal worked for Minnesota Mining and Manufacturing (3M) in the Drug Delivery Systems Division. At 3M he interfaced directly with drug discover and provided preformulation and formulation support for preclinical and clinical studies.
Dr. Myrdal’s research laboratory is centered on drug delivery with an emphasis on parenteral, aerosol and topical drug delivery. He is the director of a drug development core for a NCI program project grant that is developing topical agents for the chemoprevention of skin cancer. Dr. Myrdal has publications on a variety of aspects of preformulation, formulation and drug delivery. He is currently an expert committee member (excipients) for the United States Pharmacopoeia (USP), and is an associate editor for American Association Pharmaceutical Scientists PharmSciTech journal
Michael A. Repka, Ph.D. - ASSOCIATE EDITOR
Michael A. Repka is Chair and Professor of the Department of Pharmaceutics at The University of Mississippi, as well as Director of the Center for Pharmaceutical Technology. Dr. Repka joined the faculty at Ole Miss after receiving his Ph.D. from The University of Texas College of Pharmacy and founded a pharmaceutical research/development company that specializes in drug delivery.
His research interests include oral transmucosal and transdermal/trans-nail delivery systems, as well as other novel dosage forms. Many of these systems are directed toward the solubilization and delivery of poorly-soluble bioactives via Hot-Melt Extrusion (HME) Technology, which is a primary focus of his research. Dr. Repka's publications include over 70 peer-reviewed journal articles and book chapters and well over 250 presentations at national/international scientific meetings.
Dr. Repka serves on the Editorial Advisory Boards of six prestigious journals and has been credentialed as a member to the United States Pharmacopeial Convention. He served as Chair of the Modified Release Focus Group for 2011 and was subsequently elected Vice Chair of the Formulation Design and Development (FDD) Section within AAPS. The FDD Section is the largest section within that 12,000 member international association. He is regularly invited to speak at multi-national pharma, scientific symposia and workshops and other academic institutions on HME.
Meet the Editorial Advisory Board of AAPS PharmSciTech: A-H
Meet the Editorial Advisory Board of AAPS PharmSciTech: A-H
AAPS PharmSciTech is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.
Fernando A. Alvarez-Núñez, Ph.D.
Fernando Alvarez-Núñez, Ph.D., holds the position of scientific director at the Small Molecule Pharmaceutical Research and Development group of Amgen. His responsibilities include the leading of chemistry, manufacturing, and controls teams towards efficient and scientifically sound delivering of drug substance and drug product for all clinical phases, initial commercial batches, line extensions, and comparator trials. The execution of technology transfers and generation of relevant data for global filings are also part of his responsibilities. Prior joining Amgen, he worked for Pfizer for several years holding positions of increased responsibilities.
In addition, Alvarez-Núñez is a member of the Council of Experts of The United States Pharmacopeia 2010–2015 Excipients Chapter and holds the position of adjunct professor at University of Kansas. He has published several papers on theoretical, experimental, and industrially feasible solubilization approaches for the development of poorly soluble drug molecules. His current research focuses on the rational application of industrially feasible technologies for the formation of either physically stable amorphous phases or liquid systems with enhanced solubility and sustained supersaturation of poorly soluble drugs. His most recent publications elaborate on the manufacture of pharmaceutical relevant materials (i.e., cocrystals, salts, amorphous complex, etc.) by twin screw extrusion technology.
Alvarez-Núñez received his doctorate in pharmaceutical sciences with minor in material sciences and engineering from the University of Arizona. He obtained a Master of Science in physical chemistry from Technological Institute of Higher Studies of Monterrey, Mexico and a Bachelor of Science in pharmacy from the National University of Mexico.
Larry Augsburger, Ph.D.
Larry Augsburger is Shangraw Professor of Industrial Pharmacy and Pharmaceutics at the University of Maryland School of Pharmacy and Vice President, University Pharmaceuticals of Maryland, Inc. He received his Ph.D. from the University of Maryland and was a Senior Research Scientist for Johnson and Johnson before joining the Maryland faculty in 1969. Previous university positions have included Chair of the Department of Pharmaceutics and Director of Pharmaceutics Graduate Programs. Professor Augsburger has directed 37 graduate students and seven post-doctoral students/visiting scientists mostly in the design/formulation of immediate and extended release oral solid dosage forms.
He directed the 1991-1998 University of Maryland FDA collaborative research programs, which supported the development of FDA’s SUPAC-IR/MR guidances. As the 1999 President of AAPS, he spearheaded the establishment of AAPS’s Dietary Supplement Advisory Board, which he currently chairs. Augsburger is a past-chair of AACP’s Section of Teachers of Pharmaceutics and AAPS’s Pharmaceutical Technologies Section.
He is a fellow of AAPS, a recipient of FIP’s Industrial Pharmacy medal and AAPS’s Recognition Award for Commitment and Dedication and was named the 2001 University of Maryland Founders Week Researcher of the Year.
Sunil Battu, Ph.D.
Sunil Battu is a Senior Formulations Scientist at Mallinckrodt Pharmaceuticals, St. Louis, Missouri. He received his B.S. in Pharmacy and M.S. in Pharmaceutics from the University College of Pharmaceutical Sciences, Kakatiya University, India, and obtained his Ph.D. in Pharmaceutical Sciences from the University of Mississippi in 2010.
Dr. Battu’s research interests include development and stabilization of amorphous polymeric drug delivery systems containing poorly soluble drugs, including natural product compounds such as THC and its prodrugs, via hot-melt extrusion technology. In addition, his research activities have also focused on the pre-formulation characterization, formulation development, and process scale-up of immediate, sustained, and controlled release solid oral dosage forms, with a special emphasis on functional excipients, dry granulation/roller compaction and multi-particulate coating technologies.
Dr. Battu has authored/co-authored about 40 peer-reviewed original scientific publications, invited reviews, book chapters and conference presentations. He has been honored by election to Phi Kappa Phi and Rho Chi societies in 2007, and is a member of several scientific organizations, including the American Association of Pharmaceutical Scientists. He is also the recipient of NIH Center of Research Excellence in Natural Products Neuroscience Fellowship in 2008, and the prestigious Graduate Achievement Award from the University of Mississippi in 2010.
He is currently serving as an official reviewer of several renowned scientific journals, and has recently been selected as one of the top reviewers for the 2011 issue of the AAPS PharmSciTech journal for his outstanding efforts as a reviewer.
Robin Bogner, Ph.D.
Robin Bogner, Ph.D., is an associate professor of pharmaceutics in the Department of Pharmaceutical Science at the University of Connecticut where she is also a member of the Institute of Materials Science and a University Teaching Fellow. She received her Bachelor of Science in pharmacy from Rutgers University; her Master of Science from the University of Iowa; and her doctorate from Rutgers University, after which she joined the faculty at the University of Connecticut.
Bogner’s research interests are focused on solid dosage forms, both oral solids and parenteral lyophilized solids. In the area of oral solids, her work has involved the characterization of the microenvironment near the surface of dissolving excipients, demonstrating that the microenvironment differs significantly from the bulk fluid, not only in its pH but also its dielectric constant and viscosity, which have significant impact on the dissolution of all compounds in that microenvironment.
Her patented dissolution flow-cell is currently in use at four pharmaceutical companies. Bogner’s group has explored mesoporous silicates and amorphous solids to enhance dissolution of poorly soluble compounds. Solution mediated phase transformations of highly soluble solid forms to their less solubility forms is one focus area of her research. She has recently extended her dissolution expertise to address the unacceptably long reconstitution times of highly concentrated lyophilized protein therapeutics.
Bogner has served on the U.S. Pharmacopeial Convention’s Expert Committee and held various leadership positions at the American Association of Pharmaceutical Scientists and the America Association of Colleges of Pharmacy.
Gayle A. Brazeau, Ph.D.
Gayle A. Brazeau is Associate Professor of Pharmacy Practice and Pharmaceutical Sciences and the Associate Dean for Academic Affairs in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo, State University of New York. She received a Ph.D. in Pharmaceutics from the University at Buffalo, State University of New York in 1989 and then had faculty appointments at the University of Houston and the University of Florida, where she received teaching and student awards at both institutes.
Her research interests focus on understanding the biochemical and toxicological interactions of compounds (e.g., alcohol, cocaine), drugs (statins, antibiotics, estrogen, ERT) or excipients with skeletal muscle following intramuscular or systemic administration. Other research interests include development of intramuscular formulations (e.g., cosolvent mixtures, liposomes, microspheres, gene plasmids and in situ formulations) with reduced muscle damage upon injection without altering drug bioavailability.
Dr. Brazeau serves on several editorial advisory boards for scientific and educational journals. She has served on FDA, USP and NIH panels and committees.
Harry G. Brittain, Ph.D.
Harry G. Brittain is the Founder and Head of the Center for Pharmaceutical Physics. Prior to that he served as Director of Pharmaceutical Development at Ohmeda, Inc., and also led a variety of groups within the Analytical R & D; department at Bristol-Myers Squibb. Dr. Brittain received his Ph.D. in physical chemistry from the City University of New York (1975) and then was a postdoctoral fellow at the University of Virginia. He has held faculty positions at Ferrum College (Assistant Professor of Chemistry) and Seton Hall University (Associate Professor of Physical and Inorganic Chemistry) and has been Adjunct Professor of Pharmaceutics at Rutgers University and Visiting Research Scientist at Lehigh University.
Dr. Brittain has authored approximately 230 research publications and book chapters, and has presented 65 invited lectures in the pharmaceutical field. He is a member of the editorial boards of Pharmaceutical Research, Journal of Pharmaceutical Sciences, Pharmaceutical Development and Technology, PharmSci, Pharmaceutical Technology, Journal of Pharmaceutical and Biomedical Analysis, Chirality, and Instrumentation Science and Technology. He is also the Editor for the book series Analytical Profiles of Drug Substances and Excipients, and is Chairman of the USP Expert Committee on Excipient Monograph Content. Dr.
Brittain is a Fellow of AAPS and the recipient of the AAPS Research Achievement Award in Analysis and Pharmaceutical Quality (1998).
Stephen R. Byrn, Ph.D.
Stephen R. Byrn is Charles B. Jordan Professor at the School of Pharmacy, Purdue University and also Head of the Department of Industrial and Physical Pharmacy. His research focuses on the solid-state chemistry of drugs and has emphasized the application new instrumental techniques to pharmaceutical problems.
He is a member of the USP Council of Experts and past chair of the FDA pharmaceutical sciences advisory committee. He is also extensively involved in stability studies of solids. Professor Byrn has broad experience as a consultant in the pharmaceutical industry and is one of the founders of SSCI.
Carla M. Caramella, Ph.D.
Carla M. Caramella is professor of Pharmaceutical Technology and Biopharmacy at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Pavia, Italy. She received her Doctrate in Chemistry and Pharmaceutical Technology from the University of Pavia. Her teaching responsibilities are in undergraduate and PhD programmes, as well as in continuing education and European Union exchange activities.
Professor Caramella’s current research interests are in the design and evaluation of delivery systems and include: mucoadhesive gels for buccal and vaginal antiviral treatment, prolonged release oral dosage forms based on anionic polymer-basic drug interaction products, films for ocular therapy, mucoadhesive spray solutions for mucositic treatment, characterization of new chitosan derivatives. She has more than 160 publications, including journal and conference papers, and is co-inventor of six patents.
She currently supervises the research projects of PhD students, post-docs and visiting faculty. Professor Caramella serves on the Editorial Boards of S.T.P. Pharma Sciences, Pharmaceutical Development and Technology, Pharmaceutical Technology Europe and Bollettino Chimico Farmaceutico. She also serves as an expert appointed by the Italian Ministry of Health for the European Pharmacopea and for EMEA.
Chiao-Hsi Chiang, Ph.D
Dr. Chiao-Hsi Chiang was born in Taiwan. He received his bachelor degree in pharmacy in 1976 from National Defense Medical Center (NDMC), Taipei, Taiwan. After graduation from NDMC, he was assigned as the teaching assistant of pharmaceutics in the School of Pharmacy, NDMC. Dr. Chiang received his Ph.D. degree major in pharmaceutics in 1984 from University of Iowa, Iowa City. Since 1984, Dr. Chiang has continuously serviced in NDMC near three decades. Currently, he is the Dean and full professor of the School of Pharmacy, NDMC.
He has a long term interesting in three research areas: (1) ophthalmics development for glaucoma treatment; (2) controlled release delivery systems for optimizing oral formulations; and (3) micro- and nanoparticles as carriers for delivering protein drugs, nucleic acids and vaccines.
Dr. Chiang is a co-inventor of three Taiwan patents, including two transdermal delivery systems and one anti-glaucoma agent. He has published about 90 articles in pharmaceutics field. He also assists Taiwan pharmaceutical companies for developing more than 10 products on market.
Mahavir B. Chougule, Ph.D.
Biography: Dr. Mahavir B. Chougule, is an Assistant Professor of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at Hilo. Chougule's research is focused on development of therapeutic agent and siRNA based nanoparticle systems for the treatment of cancer and pulmonary disorders. In addition, he has experience in area of inhalation, topical and transdermal drug delivery. He has 6 years of postdoctoral research experiences and two years of Industrial research experience.
Dr. Chougule has 15 publications, 8 filed patents, 2 review article, one book chapter, and 45 scientific presentations to his credit. Dr. Chougule is serving as member of editorial board and reviewer for pharmaceutical sciences journal. He is an active member of American Association of Pharmaceutical Scientist and American Association of Cancer Research. Dr. Chougule is a recipient of several national and international awards including recent American 2011 Association of Cancer Research Minority-Serving Institution Faculty Scholar in Cancer Research Award, USA.
Research Interest: gene therapy, chemotherapy, nanotechnology based novel delivery systems, lung and breast cancer, asthma, molecular biology, tumor models,
Paolo Colombo, Ph.D.
Paolo Colombo is Professor and Head of the Pharmaceutical Department at the University of Parma, Italy. He received his Doctorate in Pharmacy from the University of Pavia in 1968 and following a Fellowship, joined the Faculty of Pharmacy at Pavia in 1971. In 1986 he joined the Faculty of Pharmacy at the University of Parma.
He has published 162 papers in the scientific literature and has filed 30 patents on pharmaceutical products. Professor Colombo is the recipient of numerous awards and honors including the Colorcon Award (1991), AAPS Fellow (1996), Outstanding Paper in J. Controlled Release (1999) and was an invited Professor at University Paris-Sud (2001).
He serves on numerous editorial boards including European Journal of Pharmaceutical Sciences, Journal Controlled Release, Pharmaceutical Research, Pharmaceutical Technology and STP Pharma Sciences. Professor Colombo is a member of FIP, EUFEPS, AAPS and APGI.
Daan Crommelin, Ph.D.
Daan Crommelin is Professor and Head of the Department of Pharmaceutics at the Utrecht University in the Netherlands. He obtained his Ph.D. at the University of Leiden in 1979 and then was a post-doctoral fellow at the University of Michigan for 2 years before joining the faculty at Utrecht where he is also Scientific Director of the Utrecht Institute for Pharmaceutical Sciences. He has published over 260 original articles, reviews and book chapters.
Professor Commelin is Deputy Managing Director of the Groningen Utrecht Institute for Drug Exploration and Adjunct Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. He has served as scientific secretary of the International Pharmacy Federation (F.I.P.) and Secretary of the Board of Pharmaceutical Sciences of the F.I.P. Professor Commelin is European Editor of Pharmaceutical Research and a member of several editorial (advisory) boards including Pharm. Research, J. Controlled Release, Pharmaceutical Technology International, Int. J. Pharmaceutics, European J. Pharm. Sciences, Pharmaceutical Development and Technology and The AAPS Journal.
He is Fellow of AAPS, recipient of the Maurice-Marie Janot Award (1995), the International Award of the Belgian Society of Pharmaceutical Sciences (1997) and a corresponding member of the Swiss Academy of Engineering Sciences. Professor Crommelin was one of the founders of OctoPlus B.V., a company focused on providing high tech pharmaceutical formulation know how, and where he acts as CSO. He is one of the managing directors of Glaucus Proteomics BV.
Damrongsak Faroongsarng, Ph.D.
Damrongsak Faroongsarng, Ph.D., received his doctorate in industrial and physical pharmacy from Purdue University in 1993. Afterwards, he took a career of professorship in the Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Thailand, and is now an associate professor. During his career, he has been teaching and conducting research in the areas of physical pharmacy and pharmaceutics with an emphasis on material characterizations, and pharmacokinetics and biopharmaceutics of oral dosage forms.
He has been a reviewer for several research projects granted by the university, the Thai Food and Drug Administration, and other national institutions. He is also a member of the university’s institutional review board. In addition to authoring articles in reputed journals, Faroongsarng has been serving as an academic peer reviewer for a number of journals including AAPS PharmSciTech.
Andrea Gazzaniga, Ph.D.
Andrea Gazzaniga is a Full Professor at the University of Milan, Italy. After graduating in 1975, he served as an Assistant Professor at the University of Pavia and attended the School of Pharmacy of the University of California, San Francisco (UCSF), as a Visiting Scientist. In 1987 he joined the University of Milan, where he teaches pharmaceutical technology and Biopharmaceutics, and supervises the research activity of numerous Ph.D. and postdoctoral students.
Professor Gazzaniga has authored over 100 research papers, 140 extended abstracts, various review articles, and holds numerous patents in pharmaceutical technology. His current research interests include the design of oral pulsatile and colon delivery systems and the characterization of solid state properties. He serves on the editorial boards of several international journals and acts as a referee for the national regulatory agency (AIFA) and as an official expert for the European Pharmacopoeia (Group12-Galenical Products).
He is a member of many scientific organizations and of the advisory board of the Italian societies Association of Industrial Pharmacists (AFI), Association of Teachers and Researchers in Pharmaceutical Technology (ADRITELF) and Interuniversity Research Consortium (TEFARCO). Dr. Gazzaniga is a fellow of the American Association of Pharmaceutical Scientists (AAPS).
Robert Gurny, Ph.D.
Robert Gurny is professor and Head of the Department of Pharmaceutical Technology and Biopharmaceutics at the University of Geneva, Switzerland, where he obtained a Ph.D. in 1976. Dr. Gurny’s research interests include the design of new carrier systems for intraocular and subretinal drug delivery of new drugs for the treatment of PVR. He is one of the pioneers in the field of drug carriers and drug targeting. In addition, he developed new degradable biopolymers, long acting implants and more recently he established a working group on gene therapy.
He is the author of more than 200 peer reviewed articles, several books and more than 80 abstracts of presentations as well as the inventor of over 25 patents. Professor Gurny’s research has been recognized by several prestigious awards such as the Merck Award in 1994, the APV Prize in 1995, the Phoenix Award in 1996 and the “Prix Roger Barré” of the University of Montreal in 1999. He is a “Fellow” of the American Association of Pharmaceutical Scientists, and is an honorary member of the Alpilles Academy.
He has served as the General Secretary of the “Controlled Release Society”, was the Vice President of the International Association for Pharmaceutical Technology (APV) and currently is the Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics.
Anthony J. Hickey, Ph.D.
Anthony Hickey is Professor of Drug Delivery and Disposition and Biomedical Engineering and Mathematics at the University of North Carolina in Chapel Hill. He obtained a Ph.D. in Pharmaceutical Sciences from the University of Aston in Birmingham (1984). Prior to his joining the University of North Carolina, Dr. Hickey held postdoctoral positions, at the University of Kentucky (1984-1988) and a faculty appointment at the University of Illinois at Chicago.
Dr. Hickey supervises a multidisciplinary group of biomedical engineers and pharmaceutical scientists studying aerosol drug delivery to, disposition in, and from the lungs. His research focuses on novel approaches to the treatment of lung diseases.
He has published over a hundred papers and chapters in the pharmaceutical and biomedical literature and has edited two texts on the subject of pharmaceutical inhalation aerosols. In 1990 he received the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists. In 2000 he was elected a Fellow of the Institute of Biology of the United Kingdom.
He is President and CEO of Cirrus Pharmaceuticals, Inc., founder of Oriel Therapeutics, Inc., a member of the scientific advisory board of several companies and of the editorial advisory boards of Critical Reviews in Drug Carrier Systems, The AAPS Journal., AAPS PharmSciTech, Pharmaceutical Technology, Pharmaceutical Research, Pharmaceutical Development and Technology and Particulate Science and Technology.
Munir Hussain, Ph.D.
Munir Hussain is a Senior Research Fellow at Bristol-Myers Squibb Company, New Brunswick, New Jersey. He received his B.S. in pharmacy from the University of Baghdad, Iraq and his Ph.D. in pharmaceutical sciences from the University of Kentucky in 1983. He holds adjunct professor appointments at the School of Pharmacy, Duquesne University; College of Pharmacy, University of Kentucky; School of Pharmacy, Temple University; College of Pharmacy, University of Tennessee; and served as a board member, College of Pharmacy and Pharmaceutical Sciences, Florida A & M University.
He serves as a member on many graduate students’ research committees. He is a member of the editorial boards of the Journal of Pharmaceutical Sciences, Journal of Pharmaceutical Development and Technology and AAPS PharmSciTech. He is the author/co-author of over 95 refereed publications in different areas of pharmaceutical sciences, 90 abstracts/national and international seminars, and holds 13 patents.
He is a Fellow of the American Association of Pharmaceutical Scientists. His research interests include drug delivery, preformulation, dissolution, formulation development and scale-up, and mechanisms of degradation and stabilizations of drugs.
Meet the Editorial Advisory Board of AAPS PharmSciTech: I-Z
Meet the Editorial Advisory Board of AAPS PharmSciTech: I-Z
AAPS PharmSciTech is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.
Peter Kleinebudde, Ph.D.
Prof. Kleinebudde studied Pharmacy at the Universities of Regensburg and Hamburg and received his German ‘Approbation’ as a pharmacist in 1983. He received his Ph.D. from the University Kiel in 1987. He then spent some years at Glaxo GmbH, Germany, in Pharmaceutical Development and Bulk Production. Between 1991 and 1997 he worked as research scientist at the University Kiel and received the German ‘Habilitation’ about work on pellets.
During a stay at the Royal Danish School of Pharmacy he was appointed as associate professor at the University Halle-Wittenberg in 1998. From 2002 to 2003 he was dean of the School of Pharmacy. In 2003 he was nominated as full professor at the Heinrich-Heine-University Duesseldorf.
He is a member of AAPS, APV, DPhG, VDI-GVC, DECHEMA and GDNÄ. Since 2002 he is president of the International Association for Pharmaceutical Technology (APV).
Prof. Kleinebudde is a member of the editorial boards of the European Journal of Pharmaceutics and Biopharmaceutics, AAPS PharmSciTech and Pharmaceutical Development and Technology. In 2004 he was designated as AAPS Fellow. He is a deputy member of the German Pharmacopoeia Commission and deputy chair of the expert group Pharmaceutical Technology. Since 2006 he is a member of the Powder Working Party of the European Pharmacopoeia.
His main research interests are solid dosage forms, especially for the pediatric population; roll compaction/ dry granulation; extrusion; pellets; functional excipients and coating processes. He has published more than 90 peer reviewed papers, 200 abstracts and conference proceedings and has given more than 140 invited lectures.
Gregory Knipp, Ph.D.
Greg graduated with a B.S. in Biochemistry from Cook College in 1988. He worked for Bristol-Myers Squibb from 1986-1991 in the Physical Pharmacy Department, where he left as a Research Associate in 1991. He joined The University of Kansas and earned his M.S. and Ph.D. in Pharmaceutical Chemistry under the supervision of Dr. Ronald Borchardt. He graduated in March of 1997 and his thesis was entitled: “The Effect of Conformation on the Passive Diffusion of Peptides across Cell Culture Models of the Intestinal Mucosa and the Blood Brain Barrier.”
He performed his postdoctoral studies from 1997-1999 in the Department of Molecular and Integrative Physiology, The University of Kansas Medical Center in the laboratory of Dr. Michael J. Soares. The focus of his research was on proteins involved in the regulation of fatty acid transfer across the rat placenta. He joined the Department of Pharmaceutics in the Ernest Mario School of Pharmacy at Rutgers University as an Assistant Professor in March of 1999.
In January of 2006, he moved his laboratory to the Department of Industrial and Physical Pharmacy at Purdue University, where he currently resides as an Associate Professor. He also serves as the Associate Director of the Dane O. Kilsdig-Center of Pharmaceutical Processing Research. His research interests include the molecular and functional characterization of human intestinal oligopeptide transporters, the effect of xenobiotics on placental fatty acid homeostasis and fetal development, and the effects of processing induced dosage form variation on clinical performance in the porcine model.
He and his laboratory have published over 45 journal articles, commentaries, and book chapters; and provided over 30 invited presentations both nationally and internationally. He is currently a member of the American Association of Colleges of Pharmacy, American Association of Pharmaceutical Scientists, American Physiological Society, International Federation of Placental Associations, and The International Society for the Study of Xenobiotics.
Kang Choon Lee, Ph.D.
Kang Choon Lee is Professor and Director of Institute of Pharmaceutical Research at SungKyunKwan University in Seoul, Korea where he earned his Ph.D. Prior to joining SungKyunKwan University in 1992, he was Professor at Chonnam National University and a industrial scientist in drug delivery development at Dong-A Pharmaceutical Company. The research focus of his Drug Targeting Laboratory has been in the areas of immunotargeting including immunotoxins, preformulation of protein and peptide drugs, and bioconjugating modification of peptide drugs.
In recent years his research activities have focused on the site-specific PEGylation of peptide drugs and delivery system development for PEGylated peptide drugs. He has served also on editorial advisory boards of Pharm Dev Tech and Pharm Res.
Ping I. Lee, Ph.D.
Ping I. Lee, Ph. D. is Professor and GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He received his Ph.D. in Physical Chemistry from Michigan State University in 1975. Since 1975 he has held research and management positions of increasing responsibilities in drug delivery and pharmaceutical R & D at Ciba-Geigy, SmithKline and Schering-Plough. He also served as a full professor in the Faculty of Pharmacy, University of Toronto from 1988 to 1993. Prior to returning to Toronto in July 2004, he was Senior Director of Pharmaceutical R & D at Schering-Plough Research Institute in Kenilworth, NJ.
Dr. Lee’s research interests include enhanced delivery of poorly soluble drugs, modified-release dosage forms, hydrogels and polymeric drug delivery systems, swellable and erodible matrix systems, kinetics and mechanisms of drug release, and diffusion and mass transfer in polymers.
He has over 65 scientific publications and 15 patents and is a former Editorial Board member of Journal of Controlled Release and European Journal of Pharmaceutical Sciences. He currently serves on the Editorial Board of Pharmaceutical Development and Technology, and AAPS PharmSciTech. He is a Fellow of the American Association for the Advancement of Science (AAAS).
Wilna Liebenberg, D.Sc.
Wilna Liebenberg, D.Sc., research professor of pharmaceutics at North-West University (South Africa), received her B.Pharm. (1984), M.Sc. (pharmaceutical chemistry, 1986) and D.Sc. (pharmaceutical chemistry, 1989) from North-West University.
She was a senior research scientist, tasked with solid-state studies, at a government laboratory for 5 years and the chief research scientist, in charge of physico-chemical characterization and research at Africa's largest pharmaceutical contract laboratory, for 9 years. She returned to full-time research in 2007 when she joined North-West University's Unit for Drug Research and Development as research professor and head of the research group SPIN (Solid-state Pharmaceutical Innovation and Nanotechnology).
Her main research focus is the solid-state characterization and optimization of pharmaceutical actives. She is the author/co-author of more than 65 publications and the inventor/co-inventor of 7 innovative products/processes that are the subject of more than 35 international patents.
She is an active member of the American Association of Pharmaceutical Scientists, the South African Pharmacy Council and the Pharmaceutical Society of South Africa.
Jim Litster, Ph.D.
Jim Litster is Professor of Chemical Engineering and of Industrial and Physical Pharmacy at Purdue University. His interests are in the area of particle technology, particularly particle design and formulation. Particle design, the production of novel particles with specific attributes is his main area of research in granulation and agglomeration. The research is targeted at several levels: particle level, rate process level and unit operation and granulation circuit level.
Dr Litster is currently conducting research projects in the area of granulation and agglomeration, including: multiscale modeling of granulation processes; regime mapping and quantitative modeling of wet granule breakage in granulators; characterization of cohesive powder flows in a mixer granulator; and design of regime separated granulators for continuous granulation. His research group at Purdue is recognized as a world leader in granulation and many of the approaches developed by his group are now widely used in engineering practice in industry, especially the pharmaceutical industry.
Dr Litster also conducts research in the recovery and delivery of bioactives, particularly by crystallization and precipitation. The targets are both small and large organic molecules (including proteins) from fermentation broths, food processing, and active pharmaceutical ingredient manufacture. These products are important as pharmaceuticals, food additives, and biocatalysts and their efficient recovery and presentation for use and delivery is a key industrial issue. His current projects in this area include: fundamental studies of the secondary nucleation of proteins; crystallization of proteins from protein mixtures; and microfluidic crystallization for particle design.
Soumyajit Majumdar, Ph.D.
Dr. Soumyajit Majumdar is an Associate Professor of Pharmaceutics and Research Associate Professor in the Research Institute of Pharmaceutical Sciences, at The University of Mississippi. He also serves as the Associate Director of the Pii Center for Pharmaceutical Technology. Dr. Majumdar received his Interdisciplinary Ph.D. in Pharmaceutical Sciences and Pharmacology from the University of Missouri Kansas City. After completing his Masters in Pharmacy (majoring in Pharmaceutics) program from Jadavpur University, India, in 1991, and prior to joining the Ph.D. program, Dr. Majumdar worked for over nine years in the pharmaceutical industry in the fields of formulation development and pharmaceutical manufacturing. Following completion of his Ph.D. program, he took up a faculty position at The University of Mississippi, School of Pharmacy, in the Fall of 2005. Dr. Majumdar’s research centers around transmucosal (buccal, sublingual, intestinal, ocular, rectal) delivery, with an emphasis on ocular drug delivery and disposition. His drug delivery strategies involve formulation approaches, chemical derivatization or prodrug design, modulation of biopharmaceutical characteristics, ADME and transporter targeted drug delivery.
Dr. Majumdar is an active member of the American Association of Pharmaceutical Scientists, Association for Research in Vision and Ophthalmology and American Association of Colleges of Pharmacy.
Walaisiri Muangsiri, PhD.
Walaisiri Muangsiri is an assistant professor and currently serves as Assistant Dean for Academic Affairs at Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand. She obtained her Pharmacy degree with Second Class Honor from Faculty of Pharmaceutical Sciences, Chulalongkorn University, in 1997, and MSc./PhD in Pharmaceutics from University of Iowa, in 2003. She is a member of Pharmacy Council of Thailand and a member in a working group responsible for making pharmacy license examination questions since 2005.
Her research interests include chemical kinetics, drug stability, polymorphism, and drug delivery systems.
Praneet Opanasopit, Ph.D.
Praneet Opanasopit, Ph.D., is reader in pharmaceutical development of Green Innovations Group, Faculty of Pharmacy, Silpakorn University in Thailand since October 2011. She joined the Department of Pharmaceutical Technology as a lecturer in pharmaceutics in October 1995 and established an international reputation for research on development and evaluation of novel drug delivery systems such as biodegradable polymeric systems, mucoadhesive polymeric materials, polymeric and lipid base nanomaterials for poorly water soluble drug, proteins and gene/siRNA, and analysis of oral and transdermal drug absorption.
Prior to her appointment at the Silpakorn University, she worked as postdoctoral research associate at The Japan Society for the Promotion of Science Postdoctoral Fellowship for Foreign Researchers, at the Institute of Advanced Biomedical Engineering and Science, School of Medicine, Tokyo Women’s Medical University, Japan (2003–2004). She received her doctorate in pharmaceutical sciences associate by Monbusho Scholarship in 2002 from the Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan (supervisor: Professor Mitsuru Hashida). Opanasopit has published over 130 original research articles.
Kamla Pathak, Ph.D.
Kamla Pathak, Ph.D., earned her doctorate in pharmaceutics in 1991 from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. With teaching and research experience of more than 22 years, Pathak currently works as professor and dean, Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, India.
She is a member of various professional bodies like the Indian Pharmaceutical Association, the Indian Hospital Pharmacists’ Association, the Association of Pharmaceutical Teachers of India, International Society for Technology in Education, and the Indian Pharmacy Graduates’ Association. Pathak is actively engaged in research on oral controlled / modulated / targeted and topical drug delivery systems and has over 150 publications in various reputed international and national peer-reviewed journals, two patents (filed), and more than 90 abstracts of papers presented in scientific forums to her credit. She is a reviewer of many international journals in the field of pharmaceutics and has handled various research projects. So far, she has guided three Ph.D.’s, more than 110 postgraduate theses, and is currently guiding five Ph.D.’s and eight Masters of Pharmacy projects. The niche areas include development of oral / topical controlled and targeted drug delivery systems.
Pathak is also credited as a reviewer of scientific projects at the Knowledge Foundation, Sweden, the Israel Science foundation, Israel, and is an invited member of American Nano Society. Awards bestowed upon her include: the 2012 “Dr. R.L. Nicore Award for Best Research Paper in Pharmaceutics,” published in the Indian Journal of Pharmaceutical Education and Research at 17th APTI Convention, Manipal; the 2012 Eminent Teacher Award at the first annual conference of the Society of Pharmaceutical Education and Research; and for various poster presentations at national pharmacy conferences held in India.
Viness Pillay, Ph.D.
Viness Pillay, Ph.D., is a Fulbright Scholar and Fellow of the African Academy of Sciences. He is a South African NRF Tier 1 Research Chair in Pharmaceutical Biomaterials and Polymer-Engineered Drug Delivery Technologies at the University of the Witwatersrand, Johannesburg, South Africa. He is also a personal full professor of pharmaceutics and head of pharmaceutics and pharmaceutics research in the Department of Pharmacy and Pharmacology.
Pillay is the director of the Wits Advanced Drug Delivery Platform, which encompasses the research, development, and eventual commercialization of innovative drug delivery systems currently under development by his research team. He is also the director of the African Network for Drugs and Diagnostics, Center of Excellence in “Advanced Drug Delivery Technology.” In addition, he is designated as the institutional director of the Wits Hub of the National Medical Devices Innovation Platform, an initiative of the Medical Research Council, Innovation Center of South Africa.
Pillay currently supervises the largest cohort of graduate students in the pharmaceutical sciences in South Africa. He also serves as a reviewer, editorial board member, and lead guest editor of international scientific journals and books. Further information may be obtained at http://www.wits.ac.za/waddp.
Feng Qian, Ph.D.
Dr. Feng Qian joined the Department of Pharmacology and Pharmaceutical Science, School of Medicine, Tsinghua University (Beijing, China) in August 2012, as a professor in pharmaceutics and drug delivery. Prior to that, Dr. Feng Qian held positions of Research Investigator, Senior Research Investigator, and Principal Scientist in the Department of Drug Product Science and Technology at Bristol-Myers Squibb Company (New Brunswick, NJ, USA) from 2003 to 2012. Dr. Qian’s research experience includes drug delivery of poorly water-soluble drugs, controlled/modified release, parenteral drug delivery, anti-cancer drug delivery, biodegradable polymers and polymeric devices. Prof. Qian’s research group in Tsinghua University will focus on two major areas: 1. the physical structure, dissolution mechanism, and in vivo performance of drug-polymer solid dispersion systems; 2. Novel drug delivery systems for pulmonary tuberculosis.
Dr. Feng Qian received his Ph.D. in Biomedical Engineering from Case Western Reserve University (Cleveland, OH, USA) in 2003, and his undergraduate education and MS degree (1998) from the Department of Materials Science and Engineering, Tsinghua University, Beijing, China. Dr. Feng Qian is an author of over 20 peer reviewed papers, 6 US patents/patent applications, and a book chapter. He has been invited to give presentations in many US and international conferences, and has severed as reviewers for multiple peer-reviewed pharmaceutical journals.
Jay Babu Ramapuram, Ph.D.
Jay Babu Ramapuram is Associate Professor of Pharmaceutics at Harrison School of Pharmacy, Auburn University. He received his Ph.D. Degree (Pharmaceutics) in 1998 from Institute of Technology, Banaras Hindu Unviersity, India.
He worked as Assistant Manager of Product Development at GlaxoSmithKline Pharmaceuticals, India. He has taught various pharmaceutics courses to Pharm D students and has taught Tablet manufacturing, formulation of protein and peptide drugs, drug products and biopharmaceutics courses at the graduate level at Auburn University. He has served/serving as major professor for four M.S. and 4 Ph.D students.
His research interests include: topical and transdermal delivery, nanoparticle formulation and characterization, excipient characterization, formulation of solid dose products, solubility improvement of drugs. He has published over 50 peer-reviewed abstracts and 50 research articles.
Dr. Ramapuram is a Postdoctoral Fellow of the American Association of Pharmaceutical Scientists and active member of Formulation and Drug Delivery Section and serve in AAPS abstract screening committees.
Jean Paul Remon, Ph.D.
Jean Paul Remon is Professor of Pharmaceutical Technology at Ghent University and currently serves as the Dean of the Faculty of Pharmaceutical Sciences and Head of the Department of Pharmaceutics. He received his Doctoral Degree in Pharmaceutical Sciences at Ghent University and was a postdoctoral fellow at the University of Keele (UK) and at the Philadelphia College of Pharmacy and Sciences (US). Further, he is a member of the Registration Commission for Veterinary Drugs and an invited lecturer at the University of Brussels.
His research focus has been on drug delivery and formulation science and he has nearly 200 peer review publications in the Pharmaceutical Sciences literature and has secured more than 14 patents. Professor Remon is a member of numerous scientific organizations including The Controlled Release Society, AAPS, Belgium Society of Pharmaceutical Sciences and the International Society of Pharmaceutical Engineering.
Carlo Rossi, Ph.D.
Carlo Rossi is Professor of Pharmaceutics at the Faculty of Pharmacy of the University of Perugia (Italy) where he received his Doctorate (Laurea) in Pharmacy in 1962. His teaching and research interests are in the areas of Pharmaceutics, Pharmaceutical Analysis, Drug Delivery, with an emphasis on colloidal dispersions, drug-membrane interactions, cell microencapsulation for xenotransplantation and sustained release dosage forms. Prior to joining the Faculty at Perugia, Professor Rossi was a Research Associate at the Chemistry Department of The Mount Sinai Hospital, New York (USA) and a Visiting Professor at the Chemistry Department of The Istituto Superiore di Sanita, Rome (Italy).
He is a Member of the Cultural Committee of the Regional Pharmacist Organization in Perugia, of the Academic Senate of the University of Perugia. and of the IDE-Turkish Contract Research Organization for Drug Information, Consultancy and Education Service. He holds membership in the Italian National Association of Pharmaceutical Technologists, the American Association of Pharmaceutical Scientists, the Controlled Release Society and the European Association of Faculties of Pharmacy European Association of Fish Pathologists (EAFP). Dr. Rossi has served as the Director of the Institute of Chemistry and Technology of Drugs at the University of Perugia and currently is Dean of the Faculty of Pharmacy and President of the Board of Deans of the Italian Faculties of Pharmacy.
Adel Sakr, Ph.D.
Adel Sakr, Ph.D., is professor of Industrial Pharmacy and Pharmaceutics and is the Director of the Industrial Pharmacy graduate program at the College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio. He received his Ph.D. in Industrial Pharmacy from the University of Strathclyde, Glasgow, U.K. He has held leading academic and industrial positions in Egypt, England, Germany, Puerto Rico, and the United States. He has advised many graduate students who presently hold leading position in academia and industry all over the world.
Dr. Sakr’s primary areas of interest include the design and optimization of extended release tablet formulations and manufacturing processes. He has published more than 146 research papers in leading national and international pharmaceutical journals. In addition, Dr. Sakr has presented more than 350 original and/or invited workshop/symposium/podium/poster presentations to national and international meetings.
Dr. Sakr is a member of Rho Chi Pharmaceutical Honor Society, the Controlled Release Society, American Pharmaceutical Association, American Association of Colleges of Pharmacy, International Federation of Pharmacy, Society of Cosmetic Chemists and The American Association of Pharmaceutical Scientists(AAPS).
He is on the editorial boards of Pharmaceutical Development and Technology, Die Pharmazie, Die Pharmazeutische Industrie, and AAPS PharmSciTech. Dr. Sakr is an elected Fellow of the AAPS and a Graduate Fellow of the University of Cincinnati. He is the recipient of the Distinguished Faculty Achievement Award of the Univeristy of Cincinnati. Dr. Sakr has been awarded Doctor Honoris Causa from Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania. Dr. Sakr is the Congress Chair, FIP-Industrial Pharmacy Section.
Claudio J. Salomon, Ph.D.
Claudio J. Salomon, Ph.D., is professor of Pharmaceutical Technology and is the Director of the Pharmacy Department at the Faculty of Biochemical and Pharmaceutical, National University of Rosario, Rosario, Argentina. He received his B.S. in pharmacy from National University of Rosario (1986). He received his Doctoral Degree in Chemistry at National University of Rosario (1993) and was a postdoctoral fellow at the Hebrew University of Jerusalem (Israel) from 1993 to 1997.
He belongs to the Argentinean National Council Research (CONICET) since 1999. His teaching responsibilities are in undergraduate and PhD programmes, as well as in Latin America-European Union exchange activities. His research interests are in the areas of Pharmaceutical Technology, Drug Delivery, and Biopharmacy with an emphasis on modified release dosage forms and microencapsulation techniques applied to drugs and microorganisms. In recent years his research activities have focused on the development of novel drug delivery systems for the treatment of several neglected diseases, including Chagas´disease.
He has published more than 30 research papers in leading international pharmaceutical and chemical journals. He serves on the editorial advisory boards of Pharmaceutical Development and Technology, Molecules and Scientia Pharmaceutica.
Eryvaldo Sócrates Tabosa do Egito, Ph. D.
Professor E. Socrates Egito received his doctoral degree in Pharmacy from the Université de Paris (Paris-Sud) in 1994. He was a pos-doc fellow at the University of Georgia, from 2001 to 2001 and actually is a Visitor Professor at the University of Florida since 2011, USA. Currently, he is Full Professor at the Universidade Federal do Rio Grande do Norte and a Researcher CNPq Fellow since 2008. He has published 72 papers in scientific journals and authored 366 presentations at national and international scientific meetings.
He has advised 15 Master of Sciences and 13 Ph. D. students. He has received 7 awards/honors and coordinated 9 sponsored research projects and several not sponsored ones. In his professional activity, he has interacted with 110 collaborators, who were co-authors in scientific works. He also has been act as a consulting for Pharmaceutical Industries and Federal Agencies of Education. His scientific studies focus mainly on pharmaceutical technology, pharmaceutical industry and pharmaceutical nanotechnology. His scientific production is focused in nanotechnology, amphotericin B, microparticles, emulsions, xylan, stability, spontaneous emulsification and HLB.
Ramesh Srirangam, Ph.D.
Ramesh Srirangam, Ph.D., is a formulations research and development scientist at Abon Pharmaceuticals. He received his bachelor’s in pharmacy and master’s in pharmaceutics from the University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India, and his doctorate in pharmaceutics from the University of Mississippi, Oxford, Mississippi in 2011. Following his master’s degree, he worked at Dr. Reddy’s Laboratories, Hyderabad, India, in the drug metabolism and pharmacokinetics division for about a year.
His major research interests include ophthalmic drug delivery and pharmacokinetics; preformulation characterization; and formulation and process development for immediate and controlled release oral, injectable, and ophthalmic products. He is author/coauthor of 15 original research publications, review articles, and a book chapter. He is a recipient of predoctoral fellowship from the National Institutes of Health, National Center for Research Resources, Centers of Biomedical Research Excellence, Center of Research Excellence in Natural Products Neuroscience in both 2007 and 2009. He is a member of national honor societies like Phi-Kappa-Phi and Rho-Chi.
He is a recipient of GP-Nair award, by Indian Drug Manufacturers Association in 2002. Srirangam is currently serving as an official reviewer of several renowned scientific journals and has recently joined the journal AAPS PharmSciTech as an editorial advisory board member.
Satyam Upandrashta, Ph.D.
Satyam Upadrashta is Executive Director, Regulatory Affairs CMC, at Forest Laboratories, Inc., in Jersey City, New Jersey. He most recently served as Director, Global Regulatory Sciences at Bristol-Myers Squibb Company. He received his B.Sc., and M. Sc., degrees in Chemistry from Osmania University, India. After seven years of industrial experience at Pfizer and Ortho Pharmaceutical Corporation, he received his Ph.D., in Pharmaceutics at the University of Iowa and then served on the pharmaceutics faculty of the University of Missouri-Kansas City.
Dr. Upadrashta’s primary research interests include polymorphism, micro-encapsulation, drug stability, solid dosage formulation and process design. He serves on the editorial advisory boards of the journals, Pharmaceutical Development and Technology and New Drugs. An active member of the AAPS, Dr. Upadrashta organized and chaired 10 technical symposia, chaired the 1997 Arden House Conference, and chaired the AAPS Pharmaceutical Technologies Section in 2000.
Peter L.D. Wildfong, Ph.D.
Peter Wildfong, assistant professor of pharmaceutics at Duquesne University, received an Hons. B.Sc. (1998) in Biochemistry from McMaster University and a Ph.D. (2004) in Industrial and Physical Pharmacy, with a graduate certificate in Materials Engineering (2004) from Purdue University. He has served as a member of the faculty committee for the National Institute of Pharmaceutical Technology and Education since 2005.
As an active member of the American Association of Pharmaceutical Scientists, he serves as a Member-at-Large on the Student, Post-Doc Outreach & Development Committee as well as advising the Duquesne student AAPS chapter.
RESEARCH SUMMARY:
Pharmaceutical materials science is an emerging discipline, which seeks to elucidate an understanding of how the fundamental structural properties of active pharmaceutical ingredients and other formulation components dictate the physical and chemical behavior of organic materials, ultimately determining the functionality of final dosage forms. A materials driven product development paradigm is not only more efficient and cost-effective, but falls in line with “quality by design” espoused by the FDA’s 21st Century Initiatives in Good Manufacturing Practices.
Current efforts in our laboratory are centered on using the crystallographic structure of small molecule organic materials to predict phenomenological behavior of pharmaceutical drug products. One avenue of interest investigates the predisposition of certain materials to undergo mechanically activated solid state phase transformations under high mechanical stresses, such as those experienced during large-scale drug product manufacturing. Facilitated increases in the systemic energy of materials are retained upon removal of the applied stresses, resulting in persistent, high-energy phases or states, which can radically affect the in vivo behavior when incorporated as part of a pharmaceutical dosage form.
A second key research area for our group involves understanding and predicting the persistence and physical stability of amorphous solid dispersions. Recognized as an effective formulation strategy for API having poor aqueous solubility, at present no models exist that can help predict whether or not an API will form a viable solid dispersion. Our group is using materials informatics and multivariate statistical phenomenological screening to establish key physicochemical properties and molecular descriptors that establish the proclivity of a given API to form an amorphous solid dispersion, in an effort to define a more universally applicable predictor of dispersion potential.
Dale Eric Wurster, Ph.D.
Dale Eric Wurster is Professor of Pharmaceutics and Professor of Chemical and Biochemical Engineering. He is also the Associate Dean for Academic Affairs in The University of Iowa Graduate College. He received his Ph.D. Degree (Physical Pharmacy) in 1979 from Purdue University. He was a member of the faculty of the University of North Carolina School of Pharmacy until 1982 when he joined The University of Iowa. Professor Wurster has taught various undergraduate pharmaceutics courses and has taught chemical kinetics, surface phenomena, and instrumental analysis at the graduate level. He has served as major professor for 26 Ph.D. graduates and one M.S. graduate, and is currently directing the thesis research of four Ph.D. students.
His research interests include: analytical applications of FTIR spectroscopy, kinetics of chemical decomposition in micellar systems, excipient characterization, solution and differential scanning calorimetry, physics of tablet compression, and surface phenomena. Within the latter category, adsorption-desorption thermodynamics and the determination of adsorbent surface composition are of special interest. He has published over 150 peer-reviewed abstracts and research articles.
Dr. Wurster is a Fellow of the American Association of Pharmaceutical Scientists, and a member of the American Chemical Society, Materials Research Society, American Association of Colleges of Pharmacy, Rho Chi Society, and Society of Sigma Xi. He serves on the Foreign Pharmacy Graduate Examination Commission of the National Association of Boards of Pharmacy and is a member of the United States Pharmacopeia Convention Committee of Experts.
Peter York, Ph.D.
Peter York is a professor at the University of Bradford, School of Pharmacy where he holds a personal chair. He received his Ph.D. in Pharmaceutical Technology from the University of London in 1973. Prior to Academe he also held a position at Glaxo Laboratories.
His research activities have spanned the pharmaceutical, particle and material sciences, with recent work focused on novel formulation processes using supercritical fluids.
Professor York has consulted widely throughout the world, published over 300 scientific articles, holds numerous patents, is a Fellow of the Royal Society of Chemistry, the Royal Pharmaceutical Society of Great Britain and the American Association of Pharmaceutical Scientists, and has received several research awards. A recent joint venture with Bradford University has been the formation (1995) of a 'hi-tech' spin-out company, bpd (Bradford Particle Design).
|
刊名字顺( Alphabetical List of Journals):
返回页首 